APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD14 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CD14 Antibody Market Analysis and Forecast 2026-2032

19 December 2025199 pages

Choose your research edition.

Industry ResearchCD14 Antibody Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal CD14 Antibody Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal CD14 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD14 Antibody Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal CD14 Antibody Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global CD14 Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CD14 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CD14 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CD14 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CD14 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CD14 Antibody include Thermo Fisher Scientific, Merck, Boster Biological Technology, Santa Cruz Biotechnology, NSJ Bioreagents, Miltenyi Biotec, Leinco Technologies, FineTest and EXBIO, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CD14 Antibody, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CD14 Antibody, also provides the revenue of main regions and countries. Of the upcoming market potential for CD14 Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CD14 Antibody revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CD14 Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CD14 Antibody revenue, projected growth trends, production technology, application and end-user industry.

CD14 Antibody Segment by Company

Thermo Fisher Scientific

Merck

Boster Biological Technology

Santa Cruz Biotechnology

NSJ Bioreagents

Miltenyi Biotec

Leinco Technologies

FineTest

EXBIO

Everest Biotech

Bio-Rad

BioLegend

Beckman Coulter

Atlas Antibodies

CD14 Antibody Segment by Type

Polyclonal

Monoclonal

CD14 Antibody Segment by Application

Immunohistochemistry Paraffin

Immunohistochemistry Frozen

Flow Cytometry

Others

CD14 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD14 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD14 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD14 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CD14 Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CD14 Antibody company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CD14 Antibody revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CD14 Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Polyclonal Major Player Table 3. Monoclonal Major Player Table 4. Global CD14 Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Immunohistochemistry Paraffin Major Player Table 6. Immunohistochemistry Frozen Major Player Table 7. Flow Cytometry Major Player Table 8. Others Major Player Table 9. CD14 Antibody Industry Trends Table 10. CD14 Antibody Industry Drivers Table 11. CD14 Antibody Industry Opportunities and Challenges Table 12. CD14 Antibody Industry Restraints Table 13. Global CD14 Antibody Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global CD14 Antibody Market Size by Region (2021-2026) & (US$ Million) Table 15. Global CD14 Antibody Market Share by Region (2021-2026) Table 16. Global CD14 Antibody Market Size by Region (2027-2032) & (US$ Million) Table 17. Global CD14 Antibody Market Share by Region (2027-2032) Table 18. Global CD14 Antibody Revenue by Players (US$ Million) & (2021-2026) Table 19. Global CD14 Antibody Revenue Market Share by Players (2021-2026) Table 20. Global CD14 Antibody Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global CD14 Antibody Key Players Headquarters & Area Served Table 22. Global CD14 Antibody Players, Product Type & Application Table 23. Global CD14 Antibody Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global CD14 Antibody by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global CD14 Antibody Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global CD14 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 28. Global CD14 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 29. Global CD14 Antibody Revenue Market Share by Type (2021-2026) Table 30. Global CD14 Antibody Revenue Market Share by Type (2027-2032) Table 31. Global CD14 Antibody Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global CD14 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 33. Global CD14 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 34. Global CD14 Antibody Revenue Market Share by Application (2021-2026) Table 35. Global CD14 Antibody Revenue Market Share by Application (2027-2032) Table 36. Thermo Fisher Scientific Company Information Table 37. Thermo Fisher Scientific Business Overview Table 38. Thermo Fisher Scientific CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Thermo Fisher Scientific CD14 Antibody Product Portfolio Table 40. Thermo Fisher Scientific Recent Development Table 41. Merck Company Information Table 42. Merck Business Overview Table 43. Merck CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Merck CD14 Antibody Product Portfolio Table 45. Merck Recent Development Table 46. Boster Biological Technology Company Information Table 47. Boster Biological Technology Business Overview Table 48. Boster Biological Technology CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Boster Biological Technology CD14 Antibody Product Portfolio Table 50. Boster Biological Technology Recent Development Table 51. Santa Cruz Biotechnology Company Information Table 52. Santa Cruz Biotechnology Business Overview Table 53. Santa Cruz Biotechnology CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Santa Cruz Biotechnology CD14 Antibody Product Portfolio Table 55. Santa Cruz Biotechnology Recent Development Table 56. NSJ Bioreagents Company Information Table 57. NSJ Bioreagents Business Overview Table 58. NSJ Bioreagents CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. NSJ Bioreagents CD14 Antibody Product Portfolio Table 60. NSJ Bioreagents Recent Development Table 61. Miltenyi Biotec Company Information Table 62. Miltenyi Biotec Business Overview Table 63. Miltenyi Biotec CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Miltenyi Biotec CD14 Antibody Product Portfolio Table 65. Miltenyi Biotec Recent Development Table 66. Leinco Technologies Company Information Table 67. Leinco Technologies Business Overview Table 68. Leinco Technologies CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Leinco Technologies CD14 Antibody Product Portfolio Table 70. Leinco Technologies Recent Development Table 71. FineTest Company Information Table 72. FineTest Business Overview Table 73. FineTest CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. FineTest CD14 Antibody Product Portfolio Table 75. FineTest Recent Development Table 76. EXBIO Company Information Table 77. EXBIO Business Overview Table 78. EXBIO CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. EXBIO CD14 Antibody Product Portfolio Table 80. EXBIO Recent Development Table 81. Everest Biotech Company Information Table 82. Everest Biotech Business Overview Table 83. Everest Biotech CD14 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Everest Biotech CD14 Antibody Product Portfolio Table 85. Everest Biotech Recent Development Table 86. Bio-Rad Company Information Table 87. Bio-Rad Business Overview Table 88. Bio-Rad CD14 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Bio-Rad CD14 Antibody Product Portfolio Table 90. Bio-Rad Recent Development Table 91. BioLegend Company Information Table 92. BioLegend Business Overview Table 93. BioLegend CD14 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. BioLegend CD14 Antibody Product Portfolio Table 95. BioLegend Recent Development Table 96. Beckman Coulter Company Information Table 97. Beckman Coulter Business Overview Table 98. Beckman Coulter CD14 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Beckman Coulter CD14 Antibody Product Portfolio Table 100. Beckman Coulter Recent Development Table 101. Atlas Antibodies Company Information Table 102. Atlas Antibodies Business Overview Table 103. Atlas Antibodies CD14 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Atlas Antibodies CD14 Antibody Product Portfolio Table 105. Atlas Antibodies Recent Development Table 106. North America CD14 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 107. North America CD14 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 108. North America CD14 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 109. North America CD14 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 110. North America CD14 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America CD14 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 112. North America CD14 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 113. Europe CD14 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 114. Europe CD14 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 115. Europe CD14 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 116. Europe CD14 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 117. Europe CD14 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Europe CD14 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 119. Europe CD14 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 120. China CD14 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 121. China CD14 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 122. China CD14 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 123. China CD14 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia CD14 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 125. Asia CD14 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 126. Asia CD14 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 127. Asia CD14 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia CD14 Antibody Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Asia CD14 Antibody Revenue by Region (US$ Million) & (2021-2026) Table 130. Asia CD14 Antibody Revenue by Region (US$ Million) & (2027-2032) Table 131. SAMEA CD14 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 132. SAMEA CD14 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 133. SAMEA CD14 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 134. SAMEA CD14 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 135. SAMEA CD14 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. SAMEA CD14 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 137. SAMEA CD14 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. CD14 Antibody Image Figure 2. Global CD14 Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD14 Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 4. Polyclonal Image Figure 5. Monoclonal Image Figure 6. Global CD14 Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global CD14 Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 8. Immunohistochemistry Paraffin Image Figure 9. Immunohistochemistry Frozen Image Figure 10. Flow Cytometry Image Figure 11. Others Image Figure 12. Global CD14 Antibody Market Size (US$ Million) & (2021-2032) Figure 13. Global CD14 Antibody Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global CD14 Antibody Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global CD14 Antibody Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global CD14 Antibody Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global CD14 Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global CD14 Antibody Revenue Market Share by Type (2021-2032) Figure 20. Global CD14 Antibody Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global CD14 Antibody Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global CD14 Antibody Revenue Market Share by Application (2021-2032) Figure 23. North America CD14 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America CD14 Antibody Revenue Share by Type (2021-2032) Figure 25. North America CD14 Antibody Revenue Share by Application (2021-2032) Figure 26. North America CD14 Antibody Revenue Share by Country (2021-2032) Figure 27. United States CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe CD14 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe CD14 Antibody Revenue Share by Type (2021-2032) Figure 32. Europe CD14 Antibody Revenue Share by Application (2021-2032) Figure 33. Europe CD14 Antibody Revenue Share by Country (2021-2032) Figure 34. Germany CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China CD14 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China CD14 Antibody Revenue Share by Type (2021-2032) Figure 44. China CD14 Antibody Revenue Share by Application (2021-2032) Figure 45. Asia CD14 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia CD14 Antibody Revenue Share by Type (2021-2032) Figure 47. Asia CD14 Antibody Revenue Share by Application (2021-2032) Figure 48. Asia CD14 Antibody Revenue Share by Region (2021-2032) Figure 49. Japan CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA CD14 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA CD14 Antibody Revenue Share by Type (2021-2032) Figure 57. SAMEA CD14 Antibody Revenue Share by Application (2021-2032) Figure 58. SAMEA CD14 Antibody Revenue Share by Country (2021-2032) Figure 59. Brazil CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt CD14 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry Paraffin
  • Immunohistochemistry Frozen
  • Flow Cytometry
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Merck
  • Boster Biological Technology
  • Santa Cruz Biotechnology
  • NSJ Bioreagents
  • Miltenyi Biotec
  • Leinco Technologies
  • FineTest
  • EXBIO
  • Everest Biotech
  • Bio-Rad
  • BioLegend
  • Beckman Coulter
  • Atlas Antibodies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CD14 Antibody Market by Type
  3. 1.2.1 Global CD14 Antibody Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Polyclonal
  5. 1.2.3 Monoclonal
  6. 1.3 CD14 Antibody Market by Application
  7. 1.3.1 Global CD14 Antibody Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Immunohistochemistry Paraffin
  9. 1.3.3 Immunohistochemistry Frozen
  10. 1.3.4 Flow Cytometry
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 CD14 Antibody Market Dynamics
  1. 2.1 CD14 Antibody Industry Trends
  2. 2.2 CD14 Antibody Industry Drivers
  3. 2.3 CD14 Antibody Industry Opportunities and Challenges
  4. 2.4 CD14 Antibody Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CD14 Antibody Market Perspective (2021-2032)
  2. 3.2 Global CD14 Antibody Growth Trends by Region
  3. 3.2.1 Global CD14 Antibody Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CD14 Antibody Market Size by Region (2021-2026)
  5. 3.2.3 Global CD14 Antibody Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CD14 Antibody Revenue by Players
  2. 4.1.1 Global CD14 Antibody Revenue by Players (2021-2026)
  3. 4.1.2 Global CD14 Antibody Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CD14 Antibody Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CD14 Antibody Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CD14 Antibody Key Players Headquarters & Area Served
  7. 4.4 Global CD14 Antibody Players, Product Type & Application
  8. 4.5 Global CD14 Antibody Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CD14 Antibody Market CR5 and HHI
  11. 4.6.3 2025 CD14 Antibody Tier 1, Tier 2, and Tier 3
5 CD14 Antibody Market Size by Type
  1. 5.1 Global CD14 Antibody Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CD14 Antibody Revenue by Type (2021-2032)
  3. 5.3 Global CD14 Antibody Revenue Market Share by Type (2021-2032)
6 CD14 Antibody Market Size by Application
  1. 6.1 Global CD14 Antibody Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CD14 Antibody Revenue by Application (2021-2032)
  3. 6.3 Global CD14 Antibody Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Thermo Fisher Scientific
  2. 7.1.1 Thermo Fisher Scientific Company Information
  3. 7.1.2 Thermo Fisher Scientific Business Overview
  4. 7.1.3 Thermo Fisher Scientific CD14 Antibody Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Thermo Fisher Scientific CD14 Antibody Product Portfolio
  6. 7.1.5 Thermo Fisher Scientific Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck CD14 Antibody Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck CD14 Antibody Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Boster Biological Technology
  14. 7.3.1 Boster Biological Technology Company Information
  15. 7.3.2 Boster Biological Technology Business Overview
  16. 7.3.3 Boster Biological Technology CD14 Antibody Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Boster Biological Technology CD14 Antibody Product Portfolio
  18. 7.3.5 Boster Biological Technology Recent Developments
  19. 7.4 Santa Cruz Biotechnology
  20. 7.4.1 Santa Cruz Biotechnology Company Information
  21. 7.4.2 Santa Cruz Biotechnology Business Overview
  22. 7.4.3 Santa Cruz Biotechnology CD14 Antibody Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Santa Cruz Biotechnology CD14 Antibody Product Portfolio
  24. 7.4.5 Santa Cruz Biotechnology Recent Developments
  25. 7.5 NSJ Bioreagents
  26. 7.5.1 NSJ Bioreagents Company Information
  27. 7.5.2 NSJ Bioreagents Business Overview
  28. 7.5.3 NSJ Bioreagents CD14 Antibody Revenue and Gross Margin (2021-2026)
  29. 7.5.4 NSJ Bioreagents CD14 Antibody Product Portfolio
  30. 7.5.5 NSJ Bioreagents Recent Developments
  31. 7.6 Miltenyi Biotec
  32. 7.6.1 Miltenyi Biotec Company Information
  33. 7.6.2 Miltenyi Biotec Business Overview
  34. 7.6.3 Miltenyi Biotec CD14 Antibody Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Miltenyi Biotec CD14 Antibody Product Portfolio
  36. 7.6.5 Miltenyi Biotec Recent Developments
  37. 7.7 Leinco Technologies
  38. 7.7.1 Leinco Technologies Company Information
  39. 7.7.2 Leinco Technologies Business Overview
  40. 7.7.3 Leinco Technologies CD14 Antibody Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Leinco Technologies CD14 Antibody Product Portfolio
  42. 7.7.5 Leinco Technologies Recent Developments
  43. 7.8 FineTest
  44. 7.8.1 FineTest Company Information
  45. 7.8.2 FineTest Business Overview
  46. 7.8.3 FineTest CD14 Antibody Revenue and Gross Margin (2021-2026)
  47. 7.8.4 FineTest CD14 Antibody Product Portfolio
  48. 7.8.5 FineTest Recent Developments
  49. 7.9 EXBIO
  50. 7.9.1 EXBIO Company Information
  51. 7.9.2 EXBIO Business Overview
  52. 7.9.3 EXBIO CD14 Antibody Revenue and Gross Margin (2021-2026)
  53. 7.9.4 EXBIO CD14 Antibody Product Portfolio
  54. 7.9.5 EXBIO Recent Developments
  55. 7.10 Everest Biotech
  56. 7.10.1 Everest Biotech Company Information
  57. 7.10.2 Everest Biotech Business Overview
  58. 7.10.3 Everest Biotech CD14 Antibody Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Everest Biotech CD14 Antibody Product Portfolio
  60. 7.10.5 Everest Biotech Recent Developments
  61. 7.11 Bio-Rad
  62. 7.11.1 Bio-Rad Company Information
  63. 7.11.2 Bio-Rad Business Overview
  64. 7.11.3 Bio-Rad CD14 Antibody Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bio-Rad CD14 Antibody Product Portfolio
  66. 7.11.5 Bio-Rad Recent Developments
  67. 7.12 BioLegend
  68. 7.12.1 BioLegend Company Information
  69. 7.12.2 BioLegend Business Overview
  70. 7.12.3 BioLegend CD14 Antibody Revenue and Gross Margin (2021-2026)
  71. 7.12.4 BioLegend CD14 Antibody Product Portfolio
  72. 7.12.5 BioLegend Recent Developments
  73. 7.13 Beckman Coulter
  74. 7.13.1 Beckman Coulter Company Information
  75. 7.13.2 Beckman Coulter Business Overview
  76. 7.13.3 Beckman Coulter CD14 Antibody Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Beckman Coulter CD14 Antibody Product Portfolio
  78. 7.13.5 Beckman Coulter Recent Developments
  79. 7.14 Atlas Antibodies
  80. 7.14.1 Atlas Antibodies Company Information
  81. 7.14.2 Atlas Antibodies Business Overview
  82. 7.14.3 Atlas Antibodies CD14 Antibody Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Atlas Antibodies CD14 Antibody Product Portfolio
  84. 7.14.5 Atlas Antibodies Recent Developments
8 North America
  1. 8.1 North America CD14 Antibody Revenue (2021-2032)
  2. 8.2 North America CD14 Antibody Revenue by Type (2021-2032)
  3. 8.2.1 North America CD14 Antibody Revenue by Type (2021-2026)
  4. 8.2.2 North America CD14 Antibody Revenue by Type (2027-2032)
  5. 8.3 North America CD14 Antibody Revenue Share by Type (2021-2032)
  6. 8.4 North America CD14 Antibody Revenue by Application (2021-2032)
  7. 8.4.1 North America CD14 Antibody Revenue by Application (2021-2026)
  8. 8.4.2 North America CD14 Antibody Revenue by Application (2027-2032)
  9. 8.5 North America CD14 Antibody Revenue Share by Application (2021-2032)
  10. 8.6 North America CD14 Antibody Revenue by Country
  11. 8.6.1 North America CD14 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CD14 Antibody Revenue by Country (2021-2026)
  13. 8.6.3 North America CD14 Antibody Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe CD14 Antibody Revenue (2021-2032)
  2. 9.2 Europe CD14 Antibody Revenue by Type (2021-2032)
  3. 9.2.1 Europe CD14 Antibody Revenue by Type (2021-2026)
  4. 9.2.2 Europe CD14 Antibody Revenue by Type (2027-2032)
  5. 9.3 Europe CD14 Antibody Revenue Share by Type (2021-2032)
  6. 9.4 Europe CD14 Antibody Revenue by Application (2021-2032)
  7. 9.4.1 Europe CD14 Antibody Revenue by Application (2021-2026)
  8. 9.4.2 Europe CD14 Antibody Revenue by Application (2027-2032)
  9. 9.5 Europe CD14 Antibody Revenue Share by Application (2021-2032)
  10. 9.6 Europe CD14 Antibody Revenue by Country
  11. 9.6.1 Europe CD14 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CD14 Antibody Revenue by Country (2021-2026)
  13. 9.6.3 Europe CD14 Antibody Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China CD14 Antibody Revenue (2021-2032)
  2. 10.2 China CD14 Antibody Revenue by Type (2021-2032)
  3. 10.2.1 China CD14 Antibody Revenue by Type (2021-2026)
  4. 10.2.2 China CD14 Antibody Revenue by Type (2027-2032)
  5. 10.3 China CD14 Antibody Revenue Share by Type (2021-2032)
  6. 10.4 China CD14 Antibody Revenue by Application (2021-2032)
  7. 10.4.1 China CD14 Antibody Revenue by Application (2021-2026)
  8. 10.4.2 China CD14 Antibody Revenue by Application (2027-2032)
  9. 10.5 China CD14 Antibody Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CD14 Antibody Revenue (2021-2032)
  2. 11.2 Asia CD14 Antibody Revenue by Type (2021-2032)
  3. 11.2.1 Asia CD14 Antibody Revenue by Type (2021-2026)
  4. 11.2.2 Asia CD14 Antibody Revenue by Type (2027-2032)
  5. 11.3 Asia CD14 Antibody Revenue Share by Type (2021-2032)
  6. 11.4 Asia CD14 Antibody Revenue by Application (2021-2032)
  7. 11.4.1 Asia CD14 Antibody Revenue by Application (2021-2026)
  8. 11.4.2 Asia CD14 Antibody Revenue by Application (2027-2032)
  9. 11.5 Asia CD14 Antibody Revenue Share by Application (2021-2032)
  10. 11.6 Asia CD14 Antibody Revenue by Country
  11. 11.6.1 Asia CD14 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CD14 Antibody Revenue by Country (2021-2026)
  13. 11.6.3 Asia CD14 Antibody Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CD14 Antibody Revenue (2021-2032)
  2. 12.2 SAMEA CD14 Antibody Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CD14 Antibody Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CD14 Antibody Revenue by Type (2027-2032)
  5. 12.3 SAMEA CD14 Antibody Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CD14 Antibody Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CD14 Antibody Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CD14 Antibody Revenue by Application (2027-2032)
  9. 12.5 SAMEA CD14 Antibody Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CD14 Antibody Revenue by Country
  11. 12.6.1 SAMEA CD14 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CD14 Antibody Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CD14 Antibody Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst